Ainos, Inc.

Ainos, Inc. is a Texas-based healthcare and technology company that combines drug development with scent-digitalization and AI sensing. Its core programs center on VELDONA, an oral low-dose interferon platform being developed for human and animal health, and AI Nose, a VOC-sensing technology intended to convert odors into digital Smell IDs. The company also has commercialized or previously commercialized products such as VELDONA Pet and a COVID-19 antigen rapid test kit, while it continues to advance new diagnostics and therapeutics through partnerships. Ainos is still in a development-heavy stage, with commercialization, licensing, and strategic collaborations used as the main path to build revenue streams.

−7 418,2 %

82,9 %

−11 897,0 %

+499,0 %

1.06

0.78

— Ainos, Inc.
%
Therapeutics0% VELDONA oral low-dose interferon programs for human diseases and animal health.
Diagnostics35% Point-of-care and rapid test products, including VOC-based and antigen testing.
Animal Health20% VELDONA Pet products sold for dogs and cats in Taiwan.
AI Sensing Platform40% AI Nose and VOC sensing technologies for digitizing scent into usable data.
Licensing and Partnerships5% Co-development, commercialization partnerships, and out-licensing of IP and pipeline assets.

Ainos sells to a mix of end users, channel partners, and development collaborators rather than relying on a single...

  • Pet owners and veterinary channelprimary

    Buy VELDONA Pet in Taiwan for companion-animal wellness uses such as skin, gum, allergy, eye, and weight-related issues.

  • Strategic co-development partnersprimary

    Purchase or help commercialize VOC sensing products and modules through the NISD and Taiwan Inabata collaboration.

  • Healthcare and diagnostics userssecondary

    Target users for AI Nose, VOC POCT, and Ainos Flora products that aim to support telehealth and point-of-care testing.

  • Pharmaceutical and clinical end marketssecondary

    Potential patients and providers for VELDONA human programs in oral warts, Sjögren’s syndrome, influenza, and mild COVID-19.

  • Industrial and robotics customersemerging

    Users of scent-digitization and VOC sensing for robotics, smart manufacturing, and environmental safety applications.

Ainos is incorporated in Texas and reports as a U.S.-based company, but its commercial activity is heavily tied to Asia...

  • •Headquartered in Texas, United States
  • •Commercial sales of VELDONA Pet in Taiwan
  • •VOC sensing revenue tied to Taiwan/Japan co-development activity
  • •Strategic partnership with a Japanese robot developer
  • •Taiwan and Japan are important for commercialization and R&D
  • •U.S. regulatory pathway remains relevant for human drug programs
  • •Foreign exchange and trade policy can affect cross-border operations

Ainos is trying to build multiple revenue streams by combining product sales, out-licensing, and strategic partnerships...

01
Commercialize AI Nose through partnershipsshort-term

Partnerships are the fastest route to market for a sensing platform that needs application-specific adoption in robotics, telehealth, and industrial settings.

02
Advance VOC POCT and Ainos Florashort-term

These products are intended to create nearer-term diagnostic revenue and validate the company’s healthcare platform.

03
Progress VELDONA clinical and licensing strategymedium-term

Clinical data and orphan-drug positioning can support future licensing, partnering, or commercialization in human therapeutics.

04
Preserve liquidity through external financingshort-term

The company needs ongoing capital to fund R&D, clinical work, and commercialization before product revenues become self-sustaining.

Ainos faces the classic risks of a development-stage biotech and diagnostics company: clinical failure, regulatory...

critical

Liquidity and financing dependence

The company states it will need additional capital and may exhaust available resources sooner than expected.

Scope
Corporate funding
Materiality
high
high

Clinical trial and development failure

VELDONA, VOC POCT, and SRNA are still being developed, so unfavorable data or delays could prevent commercialization.

Scope
Pipeline programs
Materiality
high
high

Commercial adoption risk

AI Nose and VOC sensing require partner and customer adoption in new use cases, which may take time to prove.

Scope
AI sensing and diagnostics
Materiality
high
medium

Foreign exchange volatility

Cross-border operations and sales in Asia expose results to currency movements.

Scope
Taiwan, Japan, U.S.
Materiality
medium
medium

Trade policy and tariff disruption

Tariffs, import/export restrictions, and retaliatory trade actions could raise component costs or reduce demand.

Scope
International sourcing and sales
Materiality
medium
Revenue timing and transaction mix
Makes trend analysis difficult and can distort growth rates
Stock-based compensation
Affects operating loss and comparability across periods
Convertible notes and fair value estimates
Impacts financing costs, liabilities, and earnings
Impairment testing of intangible assets
Could lead to non-cash write-downs

IONIS PHARMACEUTICALS INC

IONS · Pharmaceutical Preparations

AVANOS MEDICAL, INC.

AVNS · Orthopedic, Prosthetic & Surgical Appliances & Supplies

Global Innovative Platforms Inc.

GIPL · Surgical & Medical Instruments & Apparatus

Aligos Therapeutics, Inc.

ALGS · Biological Products, (No Diagnostic Substances)

Leidos Holdings, Inc.

LDOS · Services-Computer Integrated Systems Design

AIBOTICS, INC.

AIBT · Medicinal Chemicals & Botanical Products

: 11/08/2026